AbstractsMedical & Health Science

Introduction: Acetylsalicylic acid (ASA) is widely used drug and new studies have been published about the usefulness of ASA on a variety of diseases e.g. preeclampsia (PE). Despite substantial researches there are still a lack of information on what dose is optimum for specific groups of people e.g. obese patients and different clinical situations. The aim of this study is to observe the effect of ASA on thromboxane B2 (TxB2) and see if the effect differs between different patient groups. Secondary objective is to analyze if the effect of ASA is weight dependent in pregnant women in high risk for developing PE. Methods and data: Five participants were enrolled in the study and received 150 mg of ASA. Blood samples were collected before and after the ASA administration. TxB2 competitive enzyme immunoassay (EIA) was used to determine the TxB2 concentration in the plasma. Data obtained from the researchers of the PREDO project was analyzed using t-tests and Fisher´s exact test with respect to BMI and dose-weight relationship of the women who participated. Results: TxB2 concentration decreases significantly but increases rapidly again in first two hours of measurement, and decreases again rapidly. The TxB2 concentration appears to increase most in the obese participant. The statistical analysis results indicated that women in normal or overweight have a greater prophylactic benefit of ASA, than obese women for developing PE. Women who received ASA but developed PE had an average higher BMI than women that did not develop PE. These women also had on average lower dose-weight relationship than women who did not developed PE. Conclusion: The effects of ASA on TxB2 are evident and significant despite few participants. For prophylactic usage of ASA in obese women in high risk for developing preeclampsia it might be necessary to adjust the dose by weight, but further studies are needed. Inngangur: Asetýlsalisýlsýra (ASA) er mikið notað lyf og nýjar rannsóknir hafa verið birtar um gagnsemi þess við hinum ýmsum sjúkdómum, t.d. meðgöngueitrun (e. Preeclampsia, PE). Þrátt fyrir margar rannsóknir skortir enn upplýsingar um ákjósanlegustu skammtastærðirnar fyrir mismunandi hópa fólks t.d. offitusjúklinga og fyrir ólík klínísk einkenni. Markmið þessarar rannsóknar er að skoða hver áhrif ASA er á þromboxan B2 (TxB2) og meta hvort áhrifin séu mismunandi eftir sjúklingahópum. Annað markmið er að greina hvort áhrif ASA sé þyngdarháð hjá þunguðum konum sem eru í mikilli áhættu á að fá PE. Efniviður og aðferðir: Fimm þátttakendur voru skráðir til þátttöku og fékk hver um sig 150 mg af ASA. Blóðsýnum var safnað fyrir og eftir ASA gjöf. TxB2 samkeppnishæft ensímsónæmispróf (EIA) var notað til að ákvarða TxB2 styrk í blóði. Gögn fengin frá rannsakendum PREDO verkefnisins voru greind með t-prófi og Fisher prófi með tilliti til BMI og skammt miðað við þyngd þeirra kvenna sem tóku þátt. Niðurstöður: TxB2 styrkur minnkar verulega en eykst hratt aftur fyrstu tveimur klukkustundum frá mælingu og minnkar síðan hratt aftur. TxB2 styrkur virðist…